Search result for 'orbicular pharmaceutical technologies'

Tata Capital Healthcare Fund II invests USD 20 million in Orbicular Pharmaceutical Technologies, a Hyderabad-based company, to accelerate product development in the specialty generics space.

Gland Pharma receives USFDA approval for Eribulin Mesylate Injection, a generic breast cancer drug, expected to be the first in the market. The company plans to launch the product soon.